ReShape Lifesciences Inc.

NasdaqCM:RSLS Stock Report

Market Cap: US$3.1m

ReShape Lifesciences Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Paul Hickey

Chief executive officer

US$506.4k

Total compensation

CEO salary percentage73.7%
CEO tenure2.3yrs
CEO ownershipn/a
Management average tenure2.3yrs
Board average tenure6.4yrs

Recent management updates

Recent updates

It's A Story Of Risk Vs Reward With ReShape Lifesciences Inc. (NASDAQ:RSLS)

Apr 18
It's A Story Of Risk Vs Reward With ReShape Lifesciences Inc. (NASDAQ:RSLS)

ReShape wins FDA clearance for device used in weight loss surgery

Aug 10

Analysts Have Lowered Expectations For ReShape Lifesciences Inc. (NASDAQ:RSLS) After Its Latest Results

Mar 31
Analysts Have Lowered Expectations For ReShape Lifesciences Inc. (NASDAQ:RSLS) After Its Latest Results

Health Check: How Prudently Does ReShape Lifesciences (NASDAQ:RSLS) Use Debt?

Dec 09
Health Check: How Prudently Does ReShape Lifesciences (NASDAQ:RSLS) Use Debt?

Does ReShape Lifesciences (NASDAQ:RSLS) Have A Healthy Balance Sheet?

Aug 24
Does ReShape Lifesciences (NASDAQ:RSLS) Have A Healthy Balance Sheet?

CEO Compensation Analysis

How has Paul Hickey's remuneration changed compared to ReShape Lifesciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-US$9m

Mar 31 2024n/an/a

-US$11m

Dec 31 2023US$506kUS$373k

-US$11m

Sep 30 2023n/an/a

-US$26m

Jun 30 2023n/an/a

-US$35m

Mar 31 2023n/an/a

-US$41m

Dec 31 2022US$158kUS$133k

-US$46m

Compensation vs Market: Paul's total compensation ($USD506.42K) is about average for companies of similar size in the US market ($USD653.78K).

Compensation vs Earnings: Paul's compensation has increased whilst the company is unprofitable.

CEO

Paul Hickey (59 yo)

2.3yrs

Tenure

US$506,416

Compensation

Mr. Paul F. Hickey is Chief Executive Officer, President and Director at ReShape Lifesciences Inc. from August 15, 2022. He served as Senior Vice President of Marketing and Reimbursement at EnteroMedics In...

Leadership Team

NamePositionTenureCompensationOwnership
Dan Gladney
Executive Chair9yrsUS$129.50k0.0028%
$ 84.6
Paul Hickey
CEO, President & Director2.3yrsUS$506.42kno data
Thomas Stankovich
Senior VP & CFO5.1yrsUS$307.12k0.078%
$ 2.4k
Mark Knudson
Co-Founder and Special Advisor to the CEOno dataUS$611.80kno data
Katherine Tweden
Co-Founderno dataUS$771.78kno data
Al Diaz
Vice President of Operations and R&D3.3yrsno datano data
Dov Gal
VP of Regulatory Clinical Quality & Compliance Officerno datano datano data
Jody Dahlman
Director of Communicationsno datano datano data
Naqeeb Ansari
Senior Vice President of Global Commercial Operations2.2yrsUS$1.16mno data

2.3yrs

Average Tenure

63yo

Average Age

Experienced Management: RSLS's management team is considered experienced (2.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Dan Gladney
Executive Chair9yrsUS$129.50k0.0028%
$ 84.6
Paul Hickey
CEO, President & Director2.3yrsUS$506.42kno data
Ardaeviraf Minocherhomjee
Independent Director6.3yrsUS$52.50kno data
Gary Blackford
Independent Lead Director8.3yrsUS$77.00kno data
Philip Schauer
Member of Scientific Advisory Board6.4yrsno datano data
Caroline Apovian
Member of Scientific Advisory Board1.7yrsno datano data
Scott Shikora
Member of Scientific Advisory Board6.4yrsUS$892.19kno data
Lori McDougal
Independent Director9.3yrsUS$57.50kno data
Jaime Ponce
Member of Scientific Advisory Board6.4yrsno datano data
John Morton
Member of Scientific Advisory Board6.4yrsno datano data
Natan Zundel
Member of Scientific Advisory Board6.4yrsno datano data
Michael Baptista
Member of Scientific Advisory Board1.7yrsno datano data

6.4yrs

Average Tenure

66yo

Average Age

Experienced Board: RSLS's board of directors are considered experienced (6.4 years average tenure).